Treatment for Meningococcal CNS Infection Without Meningococcemia
For confirmed meningococcal meningitis without sepsis, treat with ceftriaxone 2 g IV every 12 hours or cefotaxime 2 g IV every 6 hours for 5 days if the patient has recovered by day 5. 1
Primary Treatment Regimen
The UK Joint Specialist Societies guideline provides clear direction for this specific clinical scenario 1:
First-line options:
- Ceftriaxone 2 g IV every 12 hours, OR
- Cefotaxime 2 g IV every 6 hours
Alternative (if cephalosporin allergy):
- Benzylpenicillin 2.4 g IV every 4 hours
- Chloramphenicol 25 mg/kg IV every 6 hours
Treatment Duration
The duration is notably shorter than other forms of bacterial meningitis 1:
- 5 days total if the patient has clinically recovered by day 5
- This applies specifically to confirmed meningococcal meningitis (not meningococcemia)
- The shorter duration reflects the excellent response of N. meningitidis to beta-lactam antibiotics
Critical Additional Measure: Eradication Therapy
If the patient is NOT treated with ceftriaxone, you must add a single dose of ciprofloxacin 500 mg orally before discharge 1. This eradicates nasopharyngeal carriage and prevents transmission to contacts. Patients who receive ceftriaxone for their meningitis treatment do not need additional prophylaxis, as ceftriaxone already achieves carriage eradication 2.
Key Clinical Distinctions
This scenario differs from meningococcal sepsis (meningococcemia) in several important ways:
- No petechial/purpuric rash indicating septicemia
- Meningeal signs present (neck stiffness, photophobia, altered consciousness)
- CSF findings confirm meningitis (elevated WBC, low glucose, positive culture/PCR)
- No hemodynamic instability or multi-organ dysfunction
The absence of septicemia means the patient has isolated CNS involvement, which typically has a better prognosis and requires shorter treatment duration compared to meningococcal sepsis.
Resistance Considerations
Meningococcal resistance to penicillin is extremely rare 1. While meningococci with reduced susceptibility to penicillin have been reported, patients infected with these strains still respond to the high doses of penicillin or cephalosporins used in meningitis treatment. This is why penicillin resistance testing and empiric vancomycin addition (required for pneumococcal meningitis in certain situations) are not necessary for meningococcal disease.
Monitoring and Outpatient Transition
Once clinically stable, outpatient intravenous therapy should be considered 1. This allows earlier hospital discharge while completing the 5-day course, improving quality of life without compromising outcomes.
Common Pitfall
Do not extend treatment beyond 5 days in patients who have recovered—this is a common error driven by the longer durations used for pneumococcal meningitis (10-14 days). Meningococcal meningitis responds rapidly to appropriate antibiotics, and prolonged therapy offers no additional benefit while increasing risks of adverse effects and healthcare costs.